Nektar Therapeutics (NKTR) Shares Bought by Toronto Dominion Bank
Toronto Dominion Bank raised its stake in shares of Nektar Therapeutics (NASDAQ:NKTR) by 17.0% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 120,803 shares of the biopharmaceutical company’s stock after acquiring an additional 17,532 shares during the period. Toronto Dominion Bank’s holdings in Nektar Therapeutics were worth $4,058,000 as of its most recent SEC filing.
A number of other institutional investors have also recently added to or reduced their stakes in NKTR. FMR LLC increased its holdings in Nektar Therapeutics by 8.5% in the 4th quarter. FMR LLC now owns 25,961,520 shares of the biopharmaceutical company’s stock worth $853,355,000 after acquiring an additional 2,041,954 shares in the last quarter. Norges Bank purchased a new stake in Nektar Therapeutics in the 4th quarter worth approximately $63,723,000. Vanguard Group Inc increased its holdings in Nektar Therapeutics by 3.6% in the 3rd quarter. Vanguard Group Inc now owns 18,922,650 shares of the biopharmaceutical company’s stock worth $1,153,525,000 after acquiring an additional 660,907 shares in the last quarter. Deutsche Bank AG increased its holdings in Nektar Therapeutics by 131.6% in the 4th quarter. Deutsche Bank AG now owns 947,004 shares of the biopharmaceutical company’s stock worth $31,125,000 after acquiring an additional 538,170 shares in the last quarter. Finally, BB Biotech AG increased its holdings in Nektar Therapeutics by 63.4% in the 4th quarter. BB Biotech AG now owns 1,380,975 shares of the biopharmaceutical company’s stock worth $45,393,000 after acquiring an additional 535,975 shares in the last quarter. 91.33% of the stock is owned by institutional investors.
NKTR traded down $0.66 during trading on Thursday, reaching $32.81. 26,951 shares of the company traded hands, compared to its average volume of 1,725,144. The company has a debt-to-equity ratio of 0.21, a current ratio of 14.94 and a quick ratio of 14.83. Nektar Therapeutics has a 12-month low of $29.22 and a 12-month high of $92.17. The firm has a market cap of $5.83 billion, a P/E ratio of 8.85 and a beta of 2.96.
Several equities research analysts recently issued reports on NKTR shares. Mizuho reissued a “buy” rating and issued a $81.00 target price on shares of Nektar Therapeutics in a report on Wednesday, January 23rd. ValuEngine lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, January 31st. HC Wainwright reaffirmed a “hold” rating and set a $47.00 price objective on shares of Nektar Therapeutics in a report on Tuesday, February 19th. BMO Capital Markets initiated coverage on shares of Nektar Therapeutics in a report on Friday, February 22nd. They set an “outperform” rating and a $75.00 price objective for the company. Finally, TheStreet raised shares of Nektar Therapeutics from a “d+” rating to a “c” rating in a report on Thursday, February 28th. One analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the company. Nektar Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $69.73.
In other news, CFO Gil M. Labrucherie sold 3,767 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $31.37, for a total transaction of $118,170.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Jillian B. Thomsen sold 1,928 shares of the stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $31.37, for a total value of $60,481.36. The disclosure for this sale can be found here. Insiders have sold a total of 26,616 shares of company stock valued at $834,944 over the last quarter. Corporate insiders own 4.31% of the company’s stock.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Featured Article: Bond
Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.